IonQ Advances to DARPA Stage C Under Potential $300M Agreement
IONQ
IonQ said on October 7 that it advanced to the final stage of DARPA’s Quantum Benchmarking Initiative and signed an agreement with a potential value of up to $300 million. Funding beyond the initial obligation remains conditional.[1]
What does the agreement cover?
Stage C is planned to run through 2029. Multiple generations of IonQ’s Superion systems will undergo DARPA’s independent verification and validation. The program tests whether quantum computers can deliver computational value greater than their cost.[1]
What does the $300 million figure mean?
The figure is a potential maximum, not a statement of cash received or revenue recognized. IonQ says funding beyond the initial obligation depends on future appropriations and DARPA funding actions.[1]
Why does it matter for IONQ?
Independent evaluation gives investors a concrete technical milestone to track. For IONQ, future system deliveries, test results and funding decisions are the next evidence to watch.[1]
Advancing to Stage C begins further testing; it does not establish that utility-scale performance has already been proven. The agreement’s timeline and process remain forward-looking.[1]
IONQ insider trading activity
In open-market trades dated in the last 90 days, no insider bought and 1 insider sold $90K, all of it under preset trading plans, per Form 4 filings.
- John W. Raymond (Director) sold 2,407 shares for $90K under a preset plan, last filed Sep 11.
Get IONQ alerts
Set a IONQ price alert, or get one when a fund, insider or politician you follow trades.
IONQ 13F fund activity
In 13F filings for the quarter ended Sep 30, 2026, 6 funds we track made a large change in IONQ: none opened or grew a position by half or more, and 6 cut one by half or more.
- D. E. Shaw & Co., Inc. cut 2,447,068 shares.
- Marshall Wace, LLP cut 2,227,477 shares.
- Millennium Management LLC cut 1,676,008 shares.
- Squarepoint Ops LLC cut 1,023,379 shares.
- Worldquant Millennium Advisors LLC cut 799,635 shares.